Several recent cases from the US Court of Appeals for the Federal Circuit offer guidance on navigating the §101 legal framework with respect to CRISPR patent claims, as Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.
- Patenting polymorphs in Mexico 11-09-2018
- Mexico’s patent linkage system: current state, effects and flaws 06-09-2018
- Patenting microorganisms in Mexico 05-09-2018
- LSIPR 50 2018: Christopher Viehbacher 31-08-2018
- LSIPR 50 2018: Frank Kalkbrenner 28-08-2018
Latest biotechnology news
Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.